지씨셀

144510KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

43.3 / 100

Reference Date: 2026-06-10

Financial Score10.0 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but ROE is below the industry average. Plunged 29.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GC Cell is a company primarily engaged in the development and commercialization of cell therapies, specimen testing, cord blood banking, bio-logging, and CDMO services. The company is focusing on the development of NK and T cell therapies and is advancing research on next-generation CAR-NK and CAR-T treatments.

Number of Employees

806people

Average Salary

48.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 48.804.0Point

PBR

1.37Industry Average 1.434.0Point

In line with industry avg

ROE

-83.81Industry Average 0.940.0Point

Well below industry avg

Debt Ratio

18.04Industry Average 12.512.0Point

Higher than industry avg (caution)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼6.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼279.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -33.0% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
듀셀, 재무·생산 임원 영입…"2028년 상장 목표"
듀셀의 재무 및 생산 임원 영입으로 IPO 준비가 가속화되어 기업 가치 상승 기대.
Positive
지씨셀, CAR-NK 세포치료제 ‘AB-201’ 첫환자 투여
지씨셀의 CAR-NK 세포치료제 AB-201의 임상 진입으로 고형암 치료 분야에서의 혁신적 진전을 보여주며 긍정적인 시장 반응 예상.
Positive
지씨셀, 고형암 정복 ‘첫발’…HER2 CAR-NK 치료제 첫 환자 ...
지씨셀이 HER2 CAR-NK 치료제의 임상 시험을 시작하며 고형암 치료 분야에서의 혁신적 진전을 보여주고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 16,500Won52-week high 27,50052-week low 16,500

1-month return0.0Point

1m -29.34% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15